Quantcast
Last updated on April 18, 2014 at 21:21 EDT

Latest Immunosuppressants Stories

2014-04-17 23:07:50

New webinar will focus on scientific and process improvements that advance Rheumatoid Arthritis (RA) drug development. This live discussion takes place on Wednesday, May 7, 2014 at 10:00am EDT (15:00 UK BST/ GMT +1). Toronto, Canada (PRWEB) April 17, 2014 Rheumatoid Arthritis (RA) is a complex and heterogeneous disease that has the potential to significantly impact morbidity, mortality and quality of life while also placing a substantial burden on healthcare systems globally. While...

2014-04-16 16:30:36

LONDON, April 16, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: PharmaPoint: Atopic Dermatitis - Global Drug Forecast and Market Analysis to 2022http://www.reportbuyer.com/pharma_healthcare/diseases/pharmapoint_atopic_dermatitis_global_drug_forecast_market_analysis_2022.htmlPharmaPoint: Atopic Dermatitis - Global Drug Forecast and Market Analysis to 2022 SummaryAlthough the past decade has seen the atopic dermatitis market remain relatively unchanged...

2014-04-16 16:26:34

LONDON, April 16, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:PharmaPoint: Atopic Dermatitis - US Drug Forecast and Market Analysis to 2022http://www.reportbuyer.com/pharma_healthcare/diseases/pharmapoint_atopic_dermatitis_us_drug_forecast_market_analysis_2022.htmlPharmaPoint: Atopic Dermatitis - US Drug Forecast and Market Analysis to 2022SummaryAlthough the past decade has seen the atopic dermatitis market remain relatively unchanged and a saturated,...

2014-04-15 12:30:07

Potential U.S. Commercialization in 2014 CHICAGO, April 15, 2014 /PRNewswire/ -- Medac Pharma, Inc., a privately held pharmaceutical company focused on the development of new molecules and improving the effectiveness of existing medicines, announced that the U.S. Food and Drug Administration (FDA) has granted approval for the name Rasuvo(TM) for the company's lead compound, MPI-2505, a subcutaneous injectable methotrexate (MTX) delivered in a ready-to-use autopen. Currently under...

2014-04-04 12:27:14

FLINT, Mich., April 4, 2014 /PRNewswire-iReach/ -- Diplomat has announced that it is one of a select group of specialty pharmacies contracted by Celgene to distribute Otezla® (apremilast), a new medication for the treatment of psoriatic arthritis. Otezla® is an oral small-molecule inhibitor of phosphodiesterase 4 (PDE4) specific for cyclic adenosine monophosphate (cAMP). Otezla® was approved by the FDA on March 21, 2014, and is available in 10 mg, 20 mg and 30 mg tablets. Diplomat...

2014-03-28 12:21:53

DUBLIN, Mar. 28, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/lwpmln/investigation ) has announced the addition of the "Investigation Report on China Tacrolimus Market, 2009-2018" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769) Tacrolimus, also named as ""FK506"" and ""FR-900506"", was developed by Fujisawa Pharmaceutical Co., Ltd. (later became Astellas Pharma by merging with Yamanouchi Pharmaceutical Co.,...

2014-03-27 12:29:39

DUBLIN, Mar. 27, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/5sfksl/therapeutic_class ) has announced the addition of the "Therapeutic Class Overview: Psoriasis - Plaque Psoriasis & Psoriatic Arthritis - Novel Oral Drugs And Biologics To Change Future Treatment Paradigm" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769) Over the last decades, therapeutic options for Plaque Psoriasis (PsO) and...

2014-03-27 08:35:29

DUBLIN, Mar. 27, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/48gc9x/therapeutic_class ) has announced the addition of the "Therapeutic Class Overview: Treating Refractory Hematological Malignancies" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769) Targeting unmet needs in the treatment of cancer/ hematological malignancies through innovative drug development strategies have witnessed favorable...

2014-03-27 08:33:57

DUBLIN, Mar. 27, 2014 /PRNewswire/ --Research and Markets (http://www.researchandmarkets.com/research/x6dsmh/therapeutic_class) has announced the addition of the "Therapeutic Class Overview : Emergence of Biogenerics Era In Japan - It's Time to Welcome Antibody Biosimilars of Foreign Origins Soon" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769) With three products and eight players already in market - Japan biosimilar market will enter new phase...

2014-03-25 20:22:11

DUBLIN, March 25, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/q29sqz/global_and ) has announced the addition of the "Global and Chinese Monoclonal Antibody Industry Report" [http://www.researchandmarkets.com/research/q29sqz/global_and ] report to their offering. <start_newscom> (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Currently, monoclonal antibody agents have been successfully used in the treatment...